SOURCE: iSatori


June 10, 2014 11:00 ET

iSatori Funds the First Ever Clinical Study on Bio-Active Peptides to Assess Their Impact on Weight-Training Performance and Recovery

GOLDEN, CO--(Marketwired - Jun 10, 2014) -  iSatori, Inc. (OTCQB: IFIT),, an emerging leader in the development and marketing of scientifically engineered nutritional supplements for healthier lifestyles, today announced it has funded the first ever clinical trial on bio-active peptides, in their commercially available Bio-Gro™ product, for its impact on weight-training performance and muscle recovery.

Stephen Adelé, founder and Chief Executive Officer of iSatori, commented, "We deployed a double-blind, placebo-controlled, randomized trial because it is the 'gold standard' of clinical studies, to determine the minimum amount of bio-active peptides (from our Bio-Gro™ product) needed to elicit a positive response with weight trainers."

The study on bio-active peptides (Bio-Gro™) has been conducted at the Institute of Exercise Physiology and Wellness Human Performance Laboratory at the University of Central Florida, in Orlando, headed up by Drs. Jay Hoffman and Jeffrey Stout. It will be presented in abstract and poster form at the International Society of Sports Nutrition ( scientific symposium on June 20 - 21, 2014, at their annual conference in Clearwater, Florida. The abstract will be posted on and, following the conference.

Director of Science and Education for iSatori, David Sandler, commented, "We are proud and excited to be the very first sports nutrition company to initiate such a study for muscular performance with the use of bio-active peptides and are certain our findings from the study will be very intriguing and promising for athletes and weight trainers alike."

iSatori is investigating funding a variety of additional studies exploring the performance benefits of bio-active peptides. "It's exciting times at iSatori and for the creation of a new category in sports nutrition with Bio-Gro™," adds Adelé.

To learn more about iSatori and Bio-Gro™, visit; or for more in-depth science on Bio-Gro™, visit As the exclusive distributor, Europa Sports, the nation's largest sports and health nutrition wholesale distributor, supplies over 14,000 specialty and independent retailers with Bio-Gro™. Retailers interested in carrying Bio-Gro™ can contact Europa Sports at 1-800-447-4795 or visit

About iSatori, Inc.

iSatori is a consumer products firm that develops and sells nutritional products through online marketing, Fortune 500 retailers, and thousands of retail stores around the world. The Company is headquartered in Golden, Colorado, and its common stock trades on the OTCQB under the symbol "IFIT." More information about the Company is available at

Forward-Looking Statements

Statements made in this news release relating to the Company's future sales, expenses, revenue, product developments, and all other statements except statements of historical fact, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We have used the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "should," "will," "potential," and similar terms and phrases to identify forward-looking statements in this press release. These statements are based on assumptions and estimates that management believes are reasonable based on currently available information; however, management's assumptions and the Company's future performance are both subject to a wide range of business risks and uncertainties, and there is no assurance that these goals and projections can or will be met. Any number of factors could cause actual results to differ materially from those in the forward-looking statements, including, but not limited to, the timing and extent of changes in demand for the Company's products, the availability and price of ingredients necessary to manufacture such products, and the outcome of any current or future litigation regarding such products or similar products of competitors. Please see our Risk Factor disclosures included in our Registration Statement on Form S-1, as amended, initially filed with the Securities and Exchange Commission on April 30, 2013, and in subsequent filings with the Securities and Exchange Commission. All future written or oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. The forward-looking statements herein speak as of the date of this press release. We undertake no obligation to update any information contained herein or to publicly release the results of any revisions to any forward-looking statements that may be made to reflect events or circumstances that occur, or that we become aware of, after the date of this press release.